4th Targeted Radiopharmaceuticals Summit US
The targeted radiopharmaceutical field is undergoing significant expansion, with progressing clinical candidates and growing novel pipelines. Precision radiopharmaceuticals represent a golden opportunity to shape the future of medicine.
As demand for radiopharmaceuticals rises, the industry is focused on strengthening isotope supply, improving patient access, and accelerating the development of therapeutic candidates.
Join us at the 4th Targeted Radiopharmaceuticals Summit US, returning to San Diego this July, as the largest end-to-end, industry-focused platform in the field.
Bringing together over 275 global stakeholders for an unparalleled opportunity to share exclusive scientific and strategic insights from leading organizations, including:
- Novartis
- AstraZeneca
- Bristol Myers Squibb (BMS)
- Ratio Therapeutics
- Alpha-9 Oncology
- AdvanCell
- Mariana Oncology
- Abdera Therapeutics
and many more!
Addressing the key challenges and opportunities in the field, this year’s summit will feature:
Cutting-Edge Engineering Techniques:
Developing novel radiopharmaceutical targeting molecules with Telix Pharmaceuticals, AI Proteins, OncoOne, and VitsGen.
Successful Clinical Translation:
Implementing phase-zero and first-in-human strategies with AdvanCell, Alpha-9 Oncology, and RayzeBio, alongside integrating real-world evidence in late-phase clinical design with UCLA, UCSF, and Convergent Tx.
Supply Chain and CMC Landscape:
Analyzing the latest dynamics of isotope availability, funding trends, and emerging technologies with William Blair and Abdera Therapeutics.
This event is an essential platform for anyone involved in the targeted radiopharmaceuticals space. Be part of the conversation that will shape the future of the industry!
